{"entity":{"id":"jan-burger","kind":"person","name":"Jan A. Burger","aka":[],"tldr":"Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.","summary":"Jan Burger is a haematologist and laboratory investigator at MD Anderson Cancer Center. He was first author of the 2015 New England Journal of Medicine report of RESONATE-2, which showed that ibrutinib improved progression-free and overall survival compared with chlorambucil in previously untreated older patients with CLL, establishing BTK inhibition as first-line therapy. His laboratory studies how the tissue microenvironment supports CLL cells.","asOf":"2026-09-18","links":[],"tags":["leukaemia","targeted-therapy","trialist"],"related":[],"cancers":["cll-treatment-naive","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["resonate-2"],"people":[],"bottlenecks":[],"keyPapers":["paper-jan-burger-n-engl-j-med-2015","paper-jan-burger-blood-2015","paper-jan-burger-blood-2009"],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Leukaemia microenvironment"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burger%5BAuthor%5D"}],"papers":[{"title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/nejmoa1509388","doi":"10.1056/nejmoa1509388","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 1283 citations on Europe PMC."},{"title":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","journal":"Blood","year":2015,"url":"https://doi.org/10.1182/blood-2014-10-606038","doi":"10.1182/blood-2014-10-606038","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 524 citations on Europe PMC."},{"title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","journal":"Blood","year":2009,"url":"https://doi.org/10.1182/blood-2009-06-225326","doi":"10.1182/blood-2009-06-225326","note":"Europe PMC author record matched by affiliation (MD Anderson Cancer Center); 426 citations on Europe PMC."}],"orcid":"0000-0002-6177-7572"},"route":"/people/jan-burger/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/"}],"paper":[{"id":"paper-jan-burger-n-engl-j-med-2015","kind":"paper","name":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","route":"/key-papers/paper-jan-burger-n-engl-j-med-2015/"},{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/"},{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/"}]}}